Levosimendan displays anti-inflammatory effects and decreases MPO bioavailability in patients with severe heart failure

[1]  Marta Elena Losa-Iglesias,et al.  Footwear used by older people and a history of hyperkeratotic lesions on the foot , 2017, Medicine.

[2]  L. Holzhauser,et al.  Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening , 2014, Heart Failure Reviews.

[3]  M. Volpe,et al.  Atrial natriuretic peptide and regulation of vascular function in hypertension and heart failure: implications for novel therapeutic strategies. , 2013, Journal of hypertension.

[4]  M. Aslan,et al.  Serum malondialdehyde levels, myeloperoxidase and catalase activities in patients with nephrotic syndrome , 2013, Redox report : communications in free radical research.

[5]  M. Sperandio,et al.  Myeloperoxidase: a leukocyte-derived protagonist of inflammation and cardiovascular disease. , 2013, Antioxidants & redox signaling.

[6]  A. Parkhomenko,et al.  Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. , 2012, International journal of cardiology.

[7]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[8]  Jiaquan Xu,et al.  Deaths: final data for 2009. , 2011, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[9]  M. Joannidis,et al.  Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study , 2011, Critical care.

[10]  C. Detter,et al.  Myeloperoxidase deficiency preserves vasomotor function in humans , 2011, European heart journal.

[11]  M. Sperandio,et al.  Myeloperoxidase attracts neutrophils by physical forces. , 2011, Blood.

[12]  A. Buser,et al.  Use of myeloperoxidase for risk stratification in acute heart failure. , 2010, Clinical chemistry.

[13]  A. Cohen-Solal,et al.  Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. , 2009, Journal of the American College of Cardiology.

[14]  F. Uberti,et al.  Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial KATP channel , 2009, British journal of pharmacology.

[15]  G. Filippatos,et al.  Novel biologic mechanisms of levosimendan and its effect on the failing heart , 2008, Expert opinion on investigational drugs.

[16]  D. Hu,et al.  Pulse Pressure and Mean Arterial Pressure in Relation to Ischemic Stroke Among Patients With Uncontrolled Hypertension in Rural Areas of China , 2008, Stroke.

[17]  G. Filippatos,et al.  Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure. , 2008, Atherosclerosis.

[18]  M. Gheorghiade,et al.  Fluid overload in acute heart failure — Re‐distribution and other mechanisms beyond fluid accumulation , 2008, European journal of heart failure.

[19]  G. Filippatos,et al.  Effects of Levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure. , 2007, Atherosclerosis.

[20]  R. Schnabel,et al.  Activation of polymorphonuclear neutrophils in patients with impaired left ventricular function. , 2007, Free radical biology & medicine.

[21]  A. Hoes,et al.  Clinical epidemiology of heart failure , 2007, Heart.

[22]  S. Hazen,et al.  Plasma myeloperoxidase levels in patients with chronic heart failure. , 2006, The American journal of cardiology.

[23]  G. Filippatos,et al.  Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. , 2006, The American journal of cardiology.

[24]  C. Abrass,et al.  Levosimendan protects against experimental endotoxemic acute renal failure. , 2006, American journal of physiology. Renal physiology.

[25]  H. Klemm,et al.  Heparins Increase Endothelial Nitric Oxide Bioavailability by Liberating Vessel-Immobilized Myeloperoxidase , 2006, Circulation.

[26]  I. Kallikazaros,et al.  The Ca2+‐sensitizer levosimendan improves oxidative damage, BNP and pro‐inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine , 2005, European journal of heart failure.

[27]  M. Safar,et al.  Vascular Development, Pulse Pressure, and the Mechanisms of Hypertension , 2005, Hypertension.

[28]  L. Pączek,et al.  Lack of relationship between interleukin-6 and CRP levels in healthy male athletes. , 2005, Immunology letters.

[29]  T. Meinertz,et al.  Systemic Endothelial Dysfunction as an Early Predictor of Adverse Outcome in Heart Failure , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[30]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[31]  Stuart D Katz,et al.  Vascular Endothelial Dysfunction and Mortality Risk in Patients With Chronic Heart Failure , 2005, Circulation.

[32]  M. Kuo,et al.  beta-Lapachone reduces endotoxin-induced macrophage activation and lung edema and mortality. , 2003, American journal of respiratory and critical care medicine.

[33]  K. Chayama,et al.  Circadian variation of blood pressure and endothelial function in patients with essential hypertension:a comparison of dippers and non-dippers. , 2002, Journal of the American College of Cardiology.

[34]  J. Cleland,et al.  Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial , 2002, The Lancet.

[35]  Chunxiang Zhang,et al.  Myeloperoxidase, a Leukocyte-Derived Vascular NO Oxidase , 2002, Science.

[36]  T. Rassaf,et al.  Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[37]  K. Kataoka,et al.  Serial circulating concentrations of c‐reactive protein, interleukin (il)‐4, and il‐6 in patients with acute left heart decompensation , 1999, Clinical cardiology.

[38]  M. Moskowitz,et al.  Hypertension in mice lacking the gene for endothelial nitric oxide synthase , 1995, Nature.

[39]  A. Ogata,et al.  Hypoxic stress induces cardiac myocyte-derived interleukin-6. , 1995, Circulation.

[40]  MA Moskowltz,et al.  Clinical epidemiology , 2008, Journal of General Internal Medicine.

[41]  D. Kereiakes,et al.  Endothelial dysfunction. , 2003, Circulation.

[42]  E. Porteri,et al.  Endothelial dysfunction in hypertension is independent from the etiology and from vascular structure. , 1998, Hypertension.